{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-083645","form_type":"8-K","ticker":"OPRX","cik":"0001448431","company_name":"OptimizeRx Corp","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.104813+00:00","generated_at":"2026-06-08T19:36:35.038360+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"OptimizeRx Q3 revenue $16.3M (+8% YoY); raises 2023 guidance, introduces 2024 outlook","bullets":["GAAP net loss per share $(0.17); non-GAAP EPS $0.09 vs $0.07 YoY.","2023 revenue guidance raised to $68-70M; adjusted EBITDA $3-4M.","Preliminary 2024 revenue guidance of at least $110M; adjusted EBITDA margin at least 10%.","Completed acquisition of Medicx Health post-Q3; total DAAP deals now at 16 for 2023.","Cash and investments $63.5M as of Sep 30, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-083645","json":"https://secwatch.observer/filing/0001213900-23-083645.json","markdown":"https://secwatch.observer/filing/0001213900-23-083645.md","text":"https://secwatch.observer/filing/0001213900-23-083645.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1448431/000121390023083645/0001213900-23-083645-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1448431/000121390023083645/ea187745-8k_optimizerx.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T19:36:35.038360+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"05d3956eee7a01b11f7c9282fbbb2e3820648697","claim":"OptimizeRx Corp reported full year 2023 results: revenue $68 million to $70 million. Guidance raised.","evidence_excerpt":"we’re increasing our guidance for 2023 and are now looking for revenue and adjusted EBITDA to come in between $68-$70 million and $3-$4 million, respectively, for the year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1448431/000121390023083645/0001213900-23-083645-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$68 million to $70 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"66233b9186e70d9770bb0dad4f3406708ca9cc31","claim":"OptimizeRx Corp reported third quarter ended September 30, 2023 results: net income $(2.9) million, EPS $(0.17).","evidence_excerpt":"● Revenue in the third quarter of 2023 increased 8% to $16.3 million, as compared to $15.1 million in the same year ago period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1448431/000121390023083645/0001213900-23-083645-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Net income","value":"$(2.9) million"},{"label":"EPS","value":"$(0.17)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"66233b9186e70d9770bb0dad4f3406708ca9cc31","claim":"OptimizeRx Corp reported third quarter ended September 30, 2023 results: net income $(2.9) million, EPS $(0.17).","evidence_excerpt":"● GAAP net loss totaled $(2.9) million or $(0.17) per basic and diluted shares outstanding in the third quarter, as compared to $(3.5) million or $(0.19) during the third quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1448431/000121390023083645/0001213900-23-083645-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Net income","value":"$(2.9) million"},{"label":"EPS","value":"$(0.17)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"6a282b111ad7f31f0d1217cadcbea72ac882bdcb","claim":"OptimizeRx Corp reported 2024 results: revenue at least $110 million. Guidance initiated.","evidence_excerpt":"We’re also introducing preliminary 2024 guidance and expect revenue to be at least $110 million and expect adjusted EBITDA margins to be at least 10%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1448431/000121390023083645/0001213900-23-083645-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2024"},{"label":"Revenue","value":"at least $110 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}